Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

@article{Motzer2009OverallSA,
  title={Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.},
  author={Robert J Motzer and Thomas E. Hutson and Piotr Tomczak and Marc Dror Michaelson and Ronald M. Bukowski and Stephane Oudard and Sylvie N{\'e}grier and Cezary A. Szczylik and Roberto Pili and Georg A. Bjarnason and Xavier Garc{\'i}a-del-Muro and Jeffrey A. Sosman and Ewa Solska and George Wilding and John A. Thompson and Sindy T. Kim and Isan Chen and Xin Huang and Robert Alan Figlin},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 22},
  pages={3584-90}
}
PURPOSE A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported. PATIENTS AND METHODS Seven hundred fifty treatment-naïve patients with metastatic clear cell RCC were randomly assigned to sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule or to IFN… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

7 Figures & Tables

Connections & Topics

Mentioned Connections BETA
A randomized , phase III trial demonstrated superiority of sunitinib over interferon alfa ( IFN - alpha ) in progression - free survival ( primary end point ) as first - line treatment for metastatic renal cell carcinoma ( RCC ) .
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma .
DiarrheaNo subtypeFatigue
The most commonly reported sunitinib - related grade 3 adverse events included hypertension ( 12% ) , fatigue ( 11% ) , diarrhea ( 9% ) , and hand - foot syndrome ( 9% ) .
FatigueNo subtypeDiarrhea
The most commonly reported sunitinib - related grade 3 adverse events included hypertension ( 12% ) , fatigue ( 11% ) , diarrhea ( 9% ) , and hand - foot syndrome ( 9% ) .
All Topics